COM:AN2THERAPEUTICS
AN2 Therapeutics
- Stock
Last Close
1.23
22/11 21:00
Market Cap
77.56M
Beta: -
Volume Today
1.25M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 597.50K - | 1.59M 166.53% | 2.40M 50.64% | |||
average receivables | 700K - | |||||
book value per share | 0.26 - | -1.45 663.18% | -2.61 80.70% | 6.22 337.87% | 5.28 15.01% | |
capex per share | ||||||
capex to depreciation | ||||||
capex to operating cash flow | ||||||
capex to revenue | ||||||
cash per share | 0.30 - | 0.29 3.01% | 3.23 1,014.15% | 6.26 93.99% | 4.55 27.40% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.00 - | 0.00 - | ||||
debt to equity | 0.00 - | 0.00 - | ||||
dividend yield | 0.01 - | |||||
earnings yield | -0.02 - | -0.06 221.96% | -0.08 22.28% | -0.28 269.02% | -0.13 52.81% | |
enterprise value | 282.99M - | 212.26M 24.99% | 267.26M 25.91% | 119.03M 55.46% | 467.92M 293.13% | |
enterprise value over ebitda | -54.65 - | -29.14 46.68% | -12.39 57.49% | -2.82 77.27% | -6.72 138.59% | |
ev to operating cash flow | -113.84 - | -39.57 65.24% | -13.05 67.03% | -3.56 72.74% | -8.78 146.86% | |
ev to sales | ||||||
free cash flow per share | -0.13 - | -0.38 187.84% | -1.13 195.73% | -2.18 93.17% | -2.26 3.51% | |
free cash flow yield | -0.01 - | -0.02 187.84% | -0.07 195.73% | -0.23 212.15% | -0.11 51.86% | |
graham net net | 0.25 - | -1.46 680.02% | -2.99 104.81% | 5.79 293.99% | 4.00 31.03% | |
graham number | 1.32 - | 5.61 325.82% | 8.34 48.64% | 19.45 133.07% | 18.06 7.14% | |
income quality | 0.44 - | 0.39 10.62% | 0.95 141.13% | 0.82 14.07% | 0.82 0.76% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -82.22 - | |||||
interest debt per share | 0.00 - | 0.04 - | ||||
inventory turnover | ||||||
invested capital | 0.00 - | 0.00 - | ||||
market cap | 288.59M - | 216.33M 25.04% | 279.35M 29.13% | 146.19M 47.67% | 483.57M 230.78% | |
net current asset value | 4.81M - | -20.32M 522.17% | -52.62M 158.97% | 91.43M 273.76% | 96.46M 5.50% | |
net debt to ebitda | 1.08 - | 0.56 48.32% | 0.56 0.35% | 0.64 14.64% | 0.22 65.04% | |
net income per share | -0.30 - | -0.97 221.96% | -1.18 22.28% | -2.70 128.36% | -2.74 1.46% | |
operating cash flow per share | -0.13 - | -0.38 187.84% | -1.13 195.73% | -2.18 93.17% | -2.26 3.51% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.99 - | -3.21 224.91% | -0.33 89.76% | -0.40 22.99% | -0.47 15.38% | |
revenue per share | ||||||
roe | -1.17 - | 0.67 157.17% | 0.45 32.33% | -0.43 196.00% | -0.52 19.38% | |
roic | -1.07 - | 0.36 133.50% | 0.45 26.56% | -0.45 198.76% | -0.56 24.66% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | 0.26 - | -1.45 663.18% | -2.61 80.70% | 6.22 337.87% | 5.28 15.01% | |
stock based compensation to revenue | ||||||
tangible asset value | 4.81M - | -20.32M 522.17% | -47.41M 133.33% | 95.37M 301.16% | 124.70M 30.75% | |
tangible book value per share | 0.26 - | -1.45 663.18% | -2.61 80.70% | 6.22 337.87% | 5.28 15.01% | |
working capital | 5.54M - | 2.77M 49.92% | 56.71M 1,943.64% | 91.44M 61.23% | 96.46M 5.50% |
All numbers in USD (except ratios and percentages)